Protara’s $45M placement; Plus, news about Eupraxia and GenSight

Pro­tara Ther­a­peu­tics rais­es $45M pri­vate place­ment: The over­sub­scribed fi­nanc­ing trans­ac­tion is set to close April 10. The pro­ceeds should ex­tend the com­pa­ny’s run­way through 2026 and help fund an on­go­ing Phase 2 tri­al of TARA-002 in high-risk non-mus­cle in­va­sive blad­der can­cer. — Ay­isha Shar­ma

Eu­prax­ia Phar­ma­ceu­ti­cals makes Nas­daq de­but: The Cana­di­an com­pa­ny, which fo­cus­es on de­vel­op­ing treat­ments for in­flam­ma­to­ry joint con­di­tions and can­cer, is now trad­ing un­der the tick­er $EPRX. Eu­prax­ia is us­ing its so-called Dif­fu­sphere tech­nol­o­gy to en­able tar­get­ed de­liv­ery of ac­tive in­gre­di­ents with ex­tend­ed ef­fect du­ra­tion and “tun­able” PK pro­files. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.